Hepion Pharmaceuticals, Inc.
HEPA- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583771
In the last 90 days, Hepion Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $0 in total; no superinvestor holds it.
Other share classesCTRVP
13F holders, Q3 2024
Institutional positions in Hepion Pharmaceuticals, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- 0 vs. Q2 2024
- Shares held
- 545.4K
- −213.4K (−28.1%) vs. Q2 2024
- Total value
- $338.2K
- −$441.1K (−56.6%) vs. Q2 2024
- New holders
- 4
- 4 more added
- Sold out
- 4
- 3 more reduced
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HEPA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $0 |
| Q1 2026 | 1 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 4 | $1.39K |
| Q1 2025 | 16 | $419.7K |
| Q4 2024 | 22 | $215.4K |
| Q3 2024 | 22 | $338.2K |
| Q2 2024 | 24 | $863.9K |
| Q1 2024 | 25 | $1.77M |
| Q4 2023 | 24 | $2.42M |
| Q3 2023 | 24 | $4.00M |
| Q2 2023 | 23 | $5.43M |
| Q1 2023 | 32 | $5.60M |
| Q4 2022 | 32 | $2.20M |
| Q3 2022 | 32 | $3.61M |
| Q2 2022 | 34 | $4.24M |
| Q1 2022 | 38 | $9.74M |
| Q4 2021 | 43 | $9.00M |
| Q3 2021 | 42 | $11.9M |
| Q2 2021 | 49 | $21.3M |
| Q1 2021 | 45 | $14.7M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Hepion Pharmaceuticals, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Anson Funds Management LP | 231,849 | $128.2K | 0.02% | +231,849 | New |
| Vanguard Group Inc | 90,922 | $60.9K | 0.00% | −36,727−28.8% | Reduced |
| BlackRock, Inc. | 82,954 | $55.6K | 0.00% | +82,954 | New |
| Geode Capital Management, LLC | 47,026 | $31.5K | 0.00% | +2,483+5.6% | Added |
| Citadel Advisors LLC | 29,307 | $19.6K | 0.00% | +29,307 | New |
| Renaissance Technologies LLC | 16,564 | $11.1K | 0.00% | +16,564 | New |
| State Street Corp | 15,676 | $10.5K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 14,640 | $9.81K | 0.00% | +20.0% | Added |
| The PNC Financial Services Group, Inc. | 7,724 | $5.17K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 6,847 | $4.59K | 0.00% | +1,041+17.9% | Added |
| Morgan Stanley | 1,357 | $909 | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 175 | $117 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 113 | $75 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 84 | $56 | 0.00% | 00.0% | Unchanged |
| AdvisorNet Financial, Inc | 63 | $42 | 0.00% | −25−28.4% | Reduced |
| Bank of America Corp | 48 | $32 | 0.00% | +2+4.3% | Added |
| Barclays PLC | 16 | $11 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 3 | $2 | 0.00% | −67−95.7% | Reduced |
| Allworth Financial LP | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Signaturefd, LLC | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Harbor Investment Advisory, LLC | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Global Retirement Partners, LLC | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −516,000−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −14,520−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −10,161−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −88−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |
| Benjamin F. Edwards & Company, Inc. | – | – | – | – | Not filed |